Amvuttra®
Amvuttra® (vutrisiran) is a prescription medicine that treats the polyneuropathy caused by an illness called hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). Amvuttra® is used in adults only. In an 18-month clinical study, Amvuttra® -treated patients showed significant improvement in nerve function and quality of life at 9 months and continued to improve throughout the study, compared with those who received placebo.
For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.
WHAT IT TREATS: |
MANUFACTURER: Alnylam Pharmaceuticals, Inc. |
CLASS: RNAi Agent |
PRESCRIBED BY: Neurologists |
HOW ADMINISTERED: Injection |
FREQUENCY: Administered once every three months. |
Length of infusion: N/A |
FOR MORE INFORMATION: |